According to the latest filing disclosed by the SEC, existing shareholders of biopharmaceutical company Tempest Therapeutics Inc. plan to resell up to 8.27 million shares of the company's common stock.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Mirae Asset cuts SamsungFN REIT stake to 13.59% from 13.78%###
Mirae Asset Global Investments cuts Mirae Asset Global REIT stake to 25.22% from 25.4%
Mirae Asset trims D&D Platform REIT stake by 290 shares to 14.22%

SpaceX (SPCX.US) sees its first signal of executive stock reduction after listing, as the President plans to sell $52 million worth of shares ahead of Starship’s first orbital test.
SpaceX President plans to sell nearly $52 million worth of shares, while transactions involving Trump's account in July have attracted attention.
